Tina Pisco filed an Elmiron lawsuit claiming that the drug caused her to develop maculopathy – a degenerative disease of the retina. According to the complaint, Pisco started taking the drug in 2012 as a treatment for interstitial cystitis. Approximately six years later, her vision rapidly deteriorated.
After being diagnosed with permanent retinal injury in both eyes, Pisco filed a suit against Johnson & Johnson Pharmaceuticals.
The lawsuit alleges the “dangerously defective prescription drug was “designed, marketed, and distributed…while knowing significant risks that were never disclosed to the medical and healthcare community,” Pisco’s complaint also adds that “Janssen Pharmaceuticals withheld material adverse events and failed to disclose the serious link between Elmiron use and significant visual damage, including pigmentary maculopathy.”
The plaintiff attorney notes that the “label and prescribing information that accompanies Elmiron when prescribed to patients contains the following: ‘Warnings: None.’”No mention of permanent vision loss or maculopathy is present on either Elmiron’s official website, prescription guide, or patient leaflet.
Neither Johnson & Johnson nor its subsidiary, Janssen Pharmaceuticals, have made any official statements regarding the case, but it is expected the company will deny wrongdoing.